Physician profile
Bruce E Christensen
NPI 1770616054
$1,237.45
in general payments reported to CMS, 2019-2025
19 companies · $581 in 2025
The $581 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2023: $280 · 2024: $240 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $180.03 | 2023-2025 | Polivy, Lunsumio, Gazyva |
| Dova Pharmaceuticals | $136.48 | 2021 | |
| Janssen Biotech, INC. | $133.48 | 2024-2025 | Rybrevant, Darzalex |
| Exelixis INC. | $125.00 | 2023 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $116.25 | 2024-2025 | Lynparza, Calquence, Tagrisso |
| Celgene Corporation | $76.91 | 2023-2025 | Reblozyl |
| Abbvie INC. | $76.05 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.13 | 2025 | Hyqvia, Vonvendi |
| Eisai INC. | $59.15 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $50.07 | 2023-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Jazz Pharmaceuticals INC. | $46.31 | 2025 | |
| Argenx US, INC. | $30.32 | 2023 | Vyvgart Hytrulo |
| Tersera Therapeutics LLC | $27.83 | 2025 | Zoladex |
| Csl Behring | $22.79 | 2025 | Privigen |
| Melinta Therapeutics, LLC | $21.22 | 2025 | Rezzayo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $18.65 | 2024 | |
| Sobi, INC | $17.46 | 2024 | |
| Tolmar, INC. | $15.16 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $15.16 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.